9 results
10-Q
2024 Q1
EX-10.9
GUTS
Fractyl Health Inc.
13 May 24
Quarterly report
4:06pm
:
Help oversee scientific projects for Revita and Rejuva; help define and execute publication and dissemination strategy for these academic … with external audiences/KOLs, investor meetings, etc.
Oversee the scientific vision for the development of the Revita and Rejuva candidates and additional
10-Q
2024 Q1
GUTS
Fractyl Health Inc.
13 May 24
Quarterly report
4:06pm
, effective January 1, 2016, and permanently repealed in December 2019;
established a new Patient-Centered Outcomes Research Institute to oversee
10-K
2023 FY
GUTS
Fractyl Health Inc.
1 Apr 24
Annual report
7:15am
criteria for Medicaid programs and created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative … January 1, 2016, and permanently repealed in December 2019;
established a new Patient-Centered Outcomes Research Institute to oversee and identify
424B4
GUTS
Fractyl Health Inc.
2 Feb 24
Prospectus supplement with pricing info
4:18pm
Outcomes Research Institute to oversee and identify priorities in comparative clinical effectiveness research in an effort to coordinate and develop … expanded eligibility criteria for Medicaid programs and created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities
S-1/A
GUTS
Fractyl Health Inc.
29 Jan 24
IPO registration (amended)
6:09am
a new Patient-Centered Outcomes Research Institute to oversee and identify priorities in comparative clinical effectiveness research in an effort … Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. In addition
S-1/A
EX-10.9
s5ailt4 kpcpl5
29 Jan 24
IPO registration (amended)
6:09am
S-1
3buk x1c3y
14 Dec 23
IPO registration
3:39pm
DRS/A
q4kgkj
21 Sep 23
Draft registration statement (amended)
12:00am
DRS/A
7lkkole6
22 Aug 23
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next